8:36 AM ET
8-K
Business Update
Azitra Business Update
Azitra has amended its Phase 1/2 clinical trial protocol for ATR-04 to expand patient eligibility to include those with rashes caused by KRAS and MEK inhibitors, as well as NF1 patients. The company also shortened required washout periods for antibiotics and steroids to accelerate patient recruitment and enrollment for Cohort 2 of the study.